Molecular Markers of Therapy-Resistant Glioblastoma and Potential Strategy to Combat Resistance

Glioblastoma (GBM) is the most common primary malignant tumor of the central nervous system. With its overall dismal prognosis (the median survival is 14 months), GBMs demonstrate a resounding resilience against all current treatment modalities. The absence of a major progress in the treatment of GB...

Descripción completa

Detalles Bibliográficos
Autores principales: Nguyen, Ha S., Shabani, Saman, Awad, Ahmed J., Kaushal, Mayank, Doan, Ninh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6032212/
https://www.ncbi.nlm.nih.gov/pubmed/29899215
http://dx.doi.org/10.3390/ijms19061765

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6032212/
https://www.ncbi.nlm.nih.gov/pubmed/29899215
http://dx.doi.org/10.3390/ijms19061765

Ejemplares similares